Tempest Therapeutics Files 2024 10-K
Ticker: TPST · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 10-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Tempest Therapeutics filed its 2024 10-K, check financials and operations.
AI Summary
Tempest Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Millendo Therapeutics, Inc. and OvaScience, Inc., is involved in pharmaceutical preparations. The filing details its business address in Brisbane, CA, and its fiscal year end. It also references various financial instruments and accounting standards.
Why It Matters
This filing provides a comprehensive overview of Tempest Therapeutics' financial health and operational status for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Tempest Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 001-35890 — SEC File Number (Company's SEC filing identifier)
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Filer
- Millendo Therapeutics, Inc. (company) — Former company name
- OvaScience, Inc. (company) — Former company name
- 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005 (location) — Business and Mail Address
- 415-798-8589 (phone_number) — Business Phone
- 2024-12-31 (date) — Fiscal Year End
- 2025-03-27 (date) — Filing Date
FAQ
What were the significant financial events or transactions for Tempest Therapeutics in fiscal year 2024?
The filing references several financial instruments and programs, including an 'At The Market Program' with Jefferies LLC initiated on June 20, 2024, and mentions Tranche B and C Term Loans from January 15, 2021, and a Term Loan from December 23, 2022.
What is Tempest Therapeutics' primary business activity?
Tempest Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When did Tempest Therapeutics change its name from its previous entities?
The company was formerly known as Millendo Therapeutics, Inc. (name change on December 7, 2018) and prior to that, OvaScience, Inc. (name change on March 8, 2012).
What accounting standards or updates are referenced in this filing?
The filing references accounting standards related to Leasehold Improvements, Accounting Standards Update 2023-07, and Chief Executive Officer members.
What is the company's physical location and contact information?
Tempest Therapeutics, Inc. is located at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005, with a business phone number of 415-798-8589.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding Tempest Therapeutics, Inc. (TPST).